Fungtional Labs

Fungtional Labs: Integrated Supply Chain for Mushroom Cultivators in North America


Fungtional Labs is a leading provider of cultivation supplies and food-grade functional mushrooms in North America. The company’s vertically integrated business model provides robust differentiation over its peers. From cultivation and extraction to testing and end-product sales and distribution, the model ensures multiple revenue streams for Fungtional Labs.

Fungtional Labs’ cultivation supplies based on its proprietary all-in-one growing media include sterilized media, spawn genetics, all-in-one grow bags, pellets and masters mix. The company’s long-term goal is to develop IP around functional and psychedelic mushroom extracts.

Revenue Streams ​Revenue Streams

Some of the company's revenue streams include selling food-grade gourmet and functional mushrooms in North America and bulk substrates, growing medias, genetics, growing equipment, which has generated significant demand among cultivators and commercial growers.

Company Highlights

  • Fungtional Labs is a vertically integrated business model that provides products from cultivation to end-product consumer sales and distribution. This provides an advantage over peers by eliminating intermediaries.
  • Fungtional Labs is a supplier of cultivation and genetic products for mushroom cultivators in North America, leveraging its proprietary all-in-one growing media. The company’s products include sterilized media, spawn genetics and all-in-one grow bags.
  • The company’s proprietary organic master mix growing media is in high demand among cultivators, providing higher yield at lower costs.
  • The company plans to implement its business model over three phases – Phase 1 will focus on providing mycological supplies and producing functional mushroom varieties; 2) Phase 2 will focus on processing finished products, as well as focus on submitting a licensed dealer application to manufacture psilocybin-enhanced products; and 3) Phase 3 will involve B2B white labelling services, as well as, operating as a licensed dealer in the psychedelics market.
  • The company’s mycological division, which supplies all-natural growth formulas and extraction methods, stands to benefit from sector tailwinds and a large addressable market. The global food fungi market is expected to grow to $69 billion by 2024, while the medicinal mushroom extract market is expected to reach $18 billion by 2024.
  • The company’s long-term goal is to develop IP around functional and psychedelic mushroom extracts. The company anticipates to provide different delivery systems to very evolving psychedelic market. The psychedelic market presents a large opportunity for the company given that the market is projected to grow at a CAGR of 16.3 percent by 2027.

This Fungtional Labs profile is part of a paid investor education campaign.*

Click here to connect with Fungtional Labs to receive an Investor Presentation

Transition Metals

Transition Metals Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Transition Metals (TSXV:XTM)

Transition Metals

Mitigating Risk. Multiplying Opportunities Across Canada’s Critical and Precious Metals

Mitigating Risk. Multiplying Opportunities Across Canada’s Critical and Precious Metals Keep Reading...
BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Sunnybrook's Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell's pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured in Nature Medicine as one of "Eleven clinical trials that will shape medicine in 2026" briacell... Keep Reading...
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT

Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell's pivotal Phase 3 study and commercial scalability potential Bria-IMT is currently being evaluated in Bria-Cell's ongoing pivotal Phase 3 study in metastatic breast cancer briacell... Keep Reading...
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the USKaleio to support brand strategies and customized commercial-readiness solutionsBria-IMT is currently being evaluated in... Keep Reading...
Syringes with measurement markings overlaid with a fluctuating blue and white line graph.

Zymeworks Expands into Respiratory Market with Theravance Buyout

Oncology-focused drugmaker Zymeworks (NASDAQ:ZYME) has agreed to acquire Theravance Biopharma (NASDAQ:TBPH) for US$929 million in cash, expanding its portfolio into the respiratory segment.The acquisition delivers Zymeworks a 35 percent US net profit share in Yupelri, the first and only... Keep Reading...
Rows of multicolored test tubes with brown, purple, blue and green caps arranged neatly on a white rack.

Merck KGaA to Acquire Bio-Techne in US$11.3 Billion Deal

Merck KGaA (ETR:MRK,OTCPL:MKGAF) has agreed to acquire life sciences supplier Bio-Techne (NASDAQ:TECH) for US$11.3 billion in cash, marking the firm’s largest transaction in a decade.Under a definitive agreement announced on Thursday (June 25), Merck KGaA will pay US$73 per share, representing a... Keep Reading...
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT

Agreement supports potential commercial readiness for Bria-IMT using Uneedle's proprietary microneedle technology for intradermal administration Technology is currently used in BriaCell's pivotal Phase 3 study and is designed to support faster, more convenient administration while enhancing the... Keep Reading...
Transition Metals

Transition Metals Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

Related News